StayHappi Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet
Marketer
Sarvagunaushdhi Pvt Ltd
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.2mg)
Overview StayHappi Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet
DiaBeta, a triple-action tablet containing glimepiride 1mg, metformin 500mg, and voglibose 0.2mg, is classified as an antidiabetic medication. This combination therapy is indicated for adult patients with type 2 diabetes mellitus to effectively manage blood glucose levels. DiaBeta should be ingested with food, consistently at the same time daily for optimal results. Dosage is determined and adjusted by your physician based on your blood sugar response. Continued use is crucial, even with seemingly controlled blood sugar, as abrupt cessation can lead to elevated glucose, increasing the risk of kidney complications, vision impairment, neuropathy, and limb loss. Remember, DiaBeta is one component of a comprehensive diabetes management plan, which necessitates a balanced diet, regular exercise, and weight management as directed by your doctor. Lifestyle choices are vital to diabetes control. Hypoglycemia (low blood sugar) is a common side effect of DiaBeta. Familiarize yourself with its symptoms – sweating, dizziness, headache, and trembling – and appropriate countermeasures. Consistent meal timing and carrying a rapid-acting glucose source (e.g., sugary snacks or juice) are crucial for prevention. Alcohol consumption should be minimized due to its potential to exacerbate hypoglycemia. Additional possible side effects include altered taste, nausea, diarrhea, abdominal discomfort, headache, edema, blurred vision, bone fractures, and upper respiratory infections. Weight gain may occur in some patients. DiaBeta is contraindicated for individuals with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Prior heart conditions should be disclosed to your physician before commencing treatment, as suitability may be affected. Pregnant or lactating women must consult their doctor before use. Regular blood glucose monitoring is essential, and your doctor may order blood tests to track blood cell counts and liver function.
Primary Ingredients of StayHappi Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet
No text provided. Please provide the text you wish me to rephrase.
Uses of StayHappi Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet
Managing type 2 diabetes
Major Benefits of StayHappi Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The StayHappi Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet should be administered on an empty stomach.
Common Side effects of StayHappi Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use StayHappi Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The StayHappi Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg tablet should be administered on an empty stomach.
How StayHappi Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet works:
Tri-action diabetes medication StayHappi, containing glimepiride (1mg), metformin (500mg), and voglibose (0.2mg) per tablet, offers a combined approach to blood sugar control.
SAFETY ADVICE
AlcoholUNSAFE
Consuming alcohol while taking StayHappi Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet is dangerous.
PregnancyCONSULT YOUR DOCTOR
The use of StayHappi Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg tablets during pregnancy may pose risks. While human research is limited, animal studies indicate potential harm to a fetus. A physician will assess the advantages against possible dangers before recommending this medication. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The use of StayHappi Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet while breastfeeding is likely inadvisable. Available human data indicates potential transfer of the medication into breast milk, posing a risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyUNSAFE
The use of StayHappi Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg tablets is likely unsafe for individuals with kidney impairment and should be omitted. Patients with severe kidney disease should especially avoid this medication. Medical advice is recommended.
LiverCAUTION
Patients with liver disease should use StayHappi Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablets cautiously, potentially requiring dosage modification. Consult a physician. For those with mild to moderate liver impairment, initiation should be at a low dose; the medication is unsuitable for patients with severe liver disease.
What if you forget to take StayHappi Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet :
Should you forget a dose of StayHappi Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet, administer it at your earliest convenience. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual medication regimen. Avoid taking a double dose.
Facts to Know About StayHappi Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
3,018 People bought this recently